1. Home
  2. PXLW vs SPRO Comparison

PXLW vs SPRO Comparison

Compare PXLW & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PXLW
  • SPRO
  • Stock Information
  • Founded
  • PXLW 1997
  • SPRO 2013
  • Country
  • PXLW United States
  • SPRO United States
  • Employees
  • PXLW N/A
  • SPRO N/A
  • Industry
  • PXLW Semiconductors
  • SPRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • PXLW Technology
  • SPRO Health Care
  • Exchange
  • PXLW Nasdaq
  • SPRO Nasdaq
  • Market Cap
  • PXLW 49.1M
  • SPRO 45.7M
  • IPO Year
  • PXLW 2000
  • SPRO 2017
  • Fundamental
  • Price
  • PXLW $0.63
  • SPRO $0.72
  • Analyst Decision
  • PXLW Strong Buy
  • SPRO Buy
  • Analyst Count
  • PXLW 3
  • SPRO 4
  • Target Price
  • PXLW $2.17
  • SPRO $5.00
  • AVG Volume (30 Days)
  • PXLW 259.5K
  • SPRO 118.7K
  • Earning Date
  • PXLW 05-13-2025
  • SPRO 03-27-2025
  • Dividend Yield
  • PXLW N/A
  • SPRO N/A
  • EPS Growth
  • PXLW N/A
  • SPRO N/A
  • EPS
  • PXLW N/A
  • SPRO N/A
  • Revenue
  • PXLW $43,206,000.00
  • SPRO $47,977,000.00
  • Revenue This Year
  • PXLW $10.25
  • SPRO N/A
  • Revenue Next Year
  • PXLW $39.19
  • SPRO N/A
  • P/E Ratio
  • PXLW N/A
  • SPRO N/A
  • Revenue Growth
  • PXLW N/A
  • SPRO N/A
  • 52 Week Low
  • PXLW $0.60
  • SPRO $0.70
  • 52 Week High
  • PXLW $2.70
  • SPRO $1.81
  • Technical
  • Relative Strength Index (RSI)
  • PXLW 36.87
  • SPRO 38.19
  • Support Level
  • PXLW $0.70
  • SPRO $0.75
  • Resistance Level
  • PXLW $0.77
  • SPRO $0.80
  • Average True Range (ATR)
  • PXLW 0.05
  • SPRO 0.05
  • MACD
  • PXLW -0.00
  • SPRO 0.00
  • Stochastic Oscillator
  • PXLW 4.53
  • SPRO 9.09

About PXLW Pixelworks Inc.

Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company operates in one segment: the design, development, marketing and sale of IC solutions for use in electronic display devices. The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in China.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: